Skip to main content

A compilation answering 50 questions on monkeypox virus and the current monkeypox outbreak.

Allergy

Authors: Beatriz Cabanillas, Giuseppe Murdaca, Amir Guemari, Maria Jose Torres, Ahmet Kursat Azkur, Emel Aksoy, Joana Vitte, Leticia de Las Vecillas, Mattia Giovannini, Ruben Fernández-Santamaria, Riccardo Castagnoli, Andrea Orsi, Rosa Amato, Irene Giberti, Alba Català, Dominika Ambrozej, Bianca Schaub, Gerdien A Tramper-Stranders, Natalija Novak, Kari C Nadeau, Ioana Agache, Mubeccel Akdis, Cezmi A Akdis

The current monkeypox disease (MPX) outbreak constitutes a new threat and challenge for our society. With more than 55,000 confirmed cases in 103 countries, World Health Organization declared the ongoing MPX outbreak a Public Health Emergency of International Concern (PHEIC) on July 23, 2022. The current MPX outbreak is the largest, most widespread, and most serious since the diagnosis of the first case of MPX in 1970 in the Democratic Republic of the Congo (DRC), a country where MPX is an endemic disease. Throughout history, there have only been sporadic and self-limiting outbreaks of MPX outside Africa, with a total of 58 cases described from 2003 to 2021. This figure contrasts with the current outbreak of 2022, in which more than 55,000 cases have been confirmed in just 4 months. MPX is, in most cases, self-limiting; however, severe clinical manifestations and complications have been reported. Complications are usually related to the extent of virus exposure and patient health status, generally affecting children, pregnant women, and immunocompromised patients. The expansive nature of the current outbreak leaves many questions that the scientific community should investigate and answer in order to understand this phenomenon better and prevent new threats in the future. In this review, 50 questions regarding monkeypox virus (MPXV) and the current MPX outbreak were answered in order to provide the most updated scientific information and to explore the potential causes and consequences of this new health threat.

© 2023 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

PMID: 36587287

Participating cluster members